Lysosomal acid lipase deficiency (LAL-D) results in progressive microvesicular hepatosteatosis,
fibrosis,
cirrhosis,
dyslipidemia, and
vascular disease. Interventions available prior to
enzyme replacement therapy development, including
lipid lowering medications,
splenectomy, hematopoietic stem cell and
liver transplantation were unsuccessful at preventing multi-systemic
disease progression, and were associated with significant morbidity and mortality. We report two sisters, diagnosed in infancy, who succumbed to LAL-D with accelerated
disease progression following
splenectomy and
liver transplantation. The index patient died one year after hematopoietic stem cell transplant and
liver transplantation. Her younger sister survived five years post
liver-transplantation, complicated by intermittent, acute rejection. Typical LAL-D hepatopathology, including progressive, microvesicular steatosis, foamy macrophage aggregates, vacuolated Kupffer cells, advanced
fibrosis and micronodular
cirrhosis recurred in the liver allograft. She died before a second
liver transplant could occur for decompensated
liver failure. Neither patient received
sebelipase alfa enzyme replacement therapy, human, recombinant,
lysosomal acid lipase enzyme, FDA approved in 2015. Here are reviewed 18 LAL-D post-
liver transplantation cases described in the literature. Multi-systemic LAL-D progression occurred in 11 patients (61%) and death in six (33%). These reports demonstrate that
liver transplantation may be necessary for LAL-D-associated
liver failure, but is not sufficient to prevent
disease progression, or
liver disease recurrence, since the pathophysiology is predominantly mediated by deficient
enzyme activity in bone marrow-derived monocyte-macrophages.
Enzyme replacement therapy addresses systemic disease and hepatopathology, potentially improving
liver-transplantation outcomes. This is the first systematic review of
liver transplantation for LAL-D, and the first account of liver allograft LAL-D-associated hepatopathology recurrence.